stoxline Quote Chart Rank Option Currency Glossary
Alkermes plc (ALKS)
24.95  -0.1 (-0.4%)    06-21 16:00
Open: 25.22
High: 25.46
Volume: 6,593,197
Pre. Close: 25.05
Low: 24.85
Market Cap: 4,222(M)
Technical analysis
2024-06-21 4:50:31 PM
Short term     
Mid term     
Targets 6-month :  29.74 1-year :  34.74
Resists First :  25.46 Second :  29.74
Pivot price 24.39
Supports First :  24.03 Second :  23.13
MAs MA(5) :  24.78 MA(20) :  24.2
MA(100) :  26.18 MA(250) :  27.2
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  71.2 D(3) :  69.3
RSI RSI(14): 55.9
52-week High :  33.7 Low :  22.01
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ALKS ] has closed below upper band by 22.0%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.52 - 25.65 25.65 - 25.75
Low: 24.5 - 24.67 24.67 - 24.81
Close: 24.71 - 24.97 24.97 - 25.18
Company Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Headline News

Sat, 22 Jun 2024
Alkermes plc (NASDAQ:ALKS) Shares Sold by Goldman Sachs Group Inc. - MarketBeat

Sat, 22 Jun 2024
Alkermes plc (NASDAQ:ALKS) Shares Acquired by Fisher Asset Management LLC - Defense World

Sat, 22 Jun 2024
Alkermes plc (NASDAQ:ALKS) Shares Sold by Goldman Sachs Group Inc. - Defense World

Fri, 21 Jun 2024
Los Angeles Capital Management LLC Acquires 122,980 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Fri, 21 Jun 2024
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? - Yahoo Lifestyle UK

Thu, 20 Jun 2024
PNC Financial Services Group Inc. Raises Position in Alkermes plc (NASDAQ:ALKS) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 169 (M)
Shares Float 161 (M)
Held by Insiders 1.2 (%)
Held by Institutions 107 (%)
Shares Short 12,940 (K)
Shares Short P.Month 13,520 (K)
Stock Financials
EPS 3.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.42
Profit Margin 25.1 %
Operating Margin 12.3 %
Return on Assets (ttm) 14.6 %
Return on Equity (ttm) 50.4 %
Qtrly Rev. Growth 21.7 %
Gross Profit (p.s.) 0
Sales Per Share 10.22
EBITDA (p.s.) 3.18
Qtrly Earnings Growth 0 %
Operating Cash Flow 444 (M)
Levered Free Cash Flow 162 (M)
Stock Valuations
PE Ratio 7.42
PEG Ratio 0.3
Price to Book value 3.36
Price to Sales 2.44
Price to Cash Flow 9.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android